New products for managing inhibitors to coagulation factors: a focus on recombinant factor VIIa concentrate.
The treatment of alloantibody and autoantibody inhibitors directed against the factor VIII coagulant protein is one of the most challenging and expensive problems in hematology. Because the currently available plasma replacement products used in this context do not control the bleeding complications in all patients, and because of the usual emergent quality of the bleeding complications, there has been a definite need to have a uniformly reliable product for instant use, which possesses a high degree of hemostatic reliability and safety. The recent introduction of recombinant factor VIIa (rFVIIa) has been a welcome addition to the pharmacologic armamentarium for the treatment of neutralizing antibodies against coagulation factors. The mechanisms of action of rFVIIa have also been interesting and have provided insight into how the coagulation pathway accomplishes adequate hemostasis. This review will discuss this new medication and place into the context of coagulation inhibitor therapy.
Kessler
C M
CM
Division of Hematology and Oncology, Georgetown University Medical Center, Washington, DC 20007, USA. kesslerc@gunet.georgetown.edu
D000906:Antibodies / Q000097:blood*; D001685:Biological Factors / Q000276:immunology*; D005167:Factor VII / Q000276:immunology; D005169:Factor VIII / Q000008:administration & dosage / Q000276:immunology; D015942:Factor VIIa / Q000008:administration & dosage / Q000009:adverse effects / Q000592:standards; D006801:Humans; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000592:standards
D000906:Antibodies; D001685:Biological Factors; D011994:Recombinant Proteins; D005167:Factor VII; D005169:Factor VIII; D015942:Factor VIIa